These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22689969)

  • 1. Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations.
    Gilsbach BK; Ho FY; Vetter IR; van Haastert PJ; Wittinghofer A; Kortholt A
    Proc Natl Acad Sci U S A; 2012 Jun; 109(26):10322-7. PubMed ID: 22689969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Parkinson disease gene LRRK2: evolutionary and structural insights.
    Marín I
    Mol Biol Evol; 2006 Dec; 23(12):2423-33. PubMed ID: 16966681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
    Reichling LJ; Riddle SM
    Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.
    Gloeckner CJ; Kinkl N; Schumacher A; Braun RJ; O'Neill E; Meitinger T; Kolch W; Prokisch H; Ueffing M
    Hum Mol Genet; 2006 Jan; 15(2):223-32. PubMed ID: 16321986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation.
    Gilsbach BK; Kortholt A
    Front Mol Neurosci; 2014; 7():32. PubMed ID: 24847205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2).
    Chan D; Citro A; Cordy JM; Shen GC; Wolozin B
    J Biol Chem; 2011 May; 286(18):16140-9. PubMed ID: 21454543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.
    West AB; Moore DJ; Biskup S; Bugayenko A; Smith WW; Ross CA; Dawson VL; Dawson TM
    Proc Natl Acad Sci U S A; 2005 Nov; 102(46):16842-7. PubMed ID: 16269541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
    Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS
    Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational heterogeneity of the Roc domains in C. tepidum Roc-COR and implications for human LRRK2 Parkinson mutations.
    Rudi K; Ho FY; Gilsbach BK; Pots H; Wittinghofer A; Kortholt A; Klare JP
    Biosci Rep; 2015 Aug; 35(5):. PubMed ID: 26310572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
    Tsika E; Moore DJ
    Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.
    Covy JP; Giasson BI
    J Neurochem; 2010 Oct; 115(1):36-46. PubMed ID: 20626563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical heterogeneity of the LRRK2 G2019S mutation.
    Papapetropoulos S; Singer C; Ross OA; Toft M; Johnson JL; Farrer MJ; Mash DC
    Arch Neurol; 2006 Sep; 63(9):1242-6. PubMed ID: 16966501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization.
    Sen S; Webber PJ; West AB
    J Biol Chem; 2009 Dec; 284(52):36346-36356. PubMed ID: 19826009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
    Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
    Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2.
    Li X; Moore DJ; Xiong Y; Dawson TM; Dawson VL
    J Biol Chem; 2010 Sep; 285(38):29569-76. PubMed ID: 20595391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2.
    Vancraenenbroeck R; Lobbestael E; Weeks SD; Strelkov SV; Baekelandt V; Taymans JM; De Maeyer M
    Biochim Biophys Acta; 2012 Mar; 1824(3):450-60. PubMed ID: 22251894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2).
    Mills RD; Mulhern TD; Liu F; Culvenor JG; Cheng HC
    Hum Mutat; 2014 Apr; 35(4):395-412. PubMed ID: 24470158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.
    Liu Z; Galemmo RA; Fraser KB; Moehle MS; Sen S; Volpicelli-Daley LA; DeLucas LJ; Ross LJ; Valiyaveettil J; Moukha-Chafiq O; Pathak AK; Ananthan S; Kezar H; White EL; Gupta V; Maddry JA; Suto MJ; West AB
    J Biol Chem; 2014 Nov; 289(47):32937-51. PubMed ID: 25228699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.
    Rudenko IN; Cookson MR
    Neurotherapeutics; 2014 Oct; 11(4):738-50. PubMed ID: 24957201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.